Latest updates for Amlif
Fresh curated links around AMLIF are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Amyloidosis Continues To Fight Back
- Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
- Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
fool.com
/1 month ago
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
seekingalpha.com
/1 month ago
Astellas Pharma Inc. (ALPMY) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
medinform.jmir.org
/3 weeks ago
Pre-Amyloidosis Red-Flag Clinical Diagnoses in Light Chain (AL) Versus Age-Related Transthyretin (ATTRwt) Amyloidosis: E...
This electronic health record–based study highlights distinct diagnostic patterns preceding a diagnosis of light chain (AL) and wild-type transthyretin (ATTRwt) amyloidosis; AL amy...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Amlif
seekingalpha.com
Recent coverage from public sources
Public source
medinform.jmir.org
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source